Sugi Predict

Sugi Predict / Compounds / SCHEMBL719830

SCHEMBL719830

SCHEMBL719830

COc1ccc(-c2cnc3[nH]c(-c4cc(OCc5ccccc5)cc(OC(C)C)c4)nc3c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCL1 Q07820 1/20 0.43
▸ MAPT P10636 2/20 0.42
▸ NPSR1 Q6W5P4 2/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ NOD2 Q9HC29 1/20 0.42
▸ GCK P35557 1/20 0.41
▸ PRMT5 O14744 2/20 0.41
▸ MAOB P27338 1/20 0.40
▸ DYRK1A Q13627 1/20 0.40
▸ DYRK1B Q9Y463 1/20 0.40
▸ FFAR4 Q5NUL3 1/20 0.39
▸ CYP2E1 P05181 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C8 P10632 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2B6 P20813 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ CHEK2 O96017 1/20 0.39
▸ MMP13 P45452 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL710173 0.93 GCK (0.44) MCL1MAPTGCKPRMT5MAOB
SCHEMBL708937 0.89 GRIN1 (0.42) MAPTNPSR1MAPK1NOD2GCK
SCHEMBL712834 0.87 MAPT (0.40) MCL1MAPTNPSR1MAPK1GCK
SCHEMBL710136 0.86 MAPT (0.43) MCL1MAPTNPSR1MAPK1NOD2
SCHEMBL720489 0.86 MAPT (0.46) MCL1MAPTNPSR1MAPK1NOD2
SCHEMBL711343 0.86 GCK (0.41) MCL1GCKMAOBDHODH
SCHEMBL711037 0.86 PRMT5 (0.44) MCL1MAPTMAPK1GCKPRMT5
SCHEMBL710843 0.85 GCK (0.41) MCL1GCKPRMT5FFAR4CHEK2
SCHEMBL710664 0.85 DHODH (0.46) MAPTNPSR1MAPK1PRMT5MAOB
SCHEMBL711041 0.85 GCK (0.43) MCL1GCKPRMT5MAOBCHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940837-B1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2012-11-07 — — EP disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 — — US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 — — US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 — — US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 — — US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 — — US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 — — US disclosed
EP-1940837-A2 IMIDAZOPYRIDINE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2008-07-09 — — EP disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS GCK, GCKR, KHK MCL1 4054/4885MAPT 3003/4885NPSR1 4489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.